Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344485 | 0.89 | MTNR1A (0.43) | MTNR1AMTNR1BNPC1RAB9ANOTUM | |
| SCHEMBL5340639 | 0.88 | MTNR1A (0.40) | MTNR1AMTNR1BNPC1RAB9ANOTUM | |
| SCHEMBL6075849 | 0.88 | MTNR1A (0.40) | MTNR1AMTNR1BNPC1RAB9ANOTUM | |
| SCHEMBL5335717 | 0.88 | MTNR1A (0.40) | MTNR1AMTNR1BNPC1RAB9ANOTUM | |
| SCHEMBL6076336 | 0.87 | MTNR1A (0.38) | MTNR1AMTNR1BNPC1RAB9ANOTUM | |
| SCHEMBL6076333 | 0.87 | MTNR1A (0.38) | MTNR1AMTNR1BNPC1RAB9ANOTUM | |
| SCHEMBL8137801 | 0.86 | MTNR1A (0.54) | MTNR1AMTNR1B | |
| SCHEMBL5351402 | 0.84 | MTNR1A (0.39) | MTNR1AMTNR1BNPC1RAB9A | |
| SCHEMBL6076079 | 0.80 | PLA2G7 (0.41) | MTNR1AMTNR1BNPC1RAB9APTGDR2 | |
| SCHEMBL5352068 | 0.79 | EGFR (0.44) | MTNR1AMTNR1BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | CNR2 140/4885MTNR1A 465/4885MTNR1B 414/4885 |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | CNR2 55/4885MTNR1A 388/4885MTNR1B 325/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | CNR2 140/4885MTNR1A 465/4885MTNR1B 414/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | CNR2 49/4885MTNR1A 409/4885MTNR1B 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.